NASDAQ:CFMS

Conformis - CFMS Stock Forecast, Price & News

$0.36

-0.01 (-2.68%)

(As of 08/15/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.35
▼
$0.38
50-Day Range: $0.26
▼
$0.40
52-Week Range: $0.25
▼
$1.96

Volume: 646,175 shs
Average Volume: 1.35 million shs
Market Capitalization: $68.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.50

Conformis MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 313.7% Upside
$1.50 Price Target
Short Interest: Healthy
0.96% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.15
Based on 17 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.32) to ($0.25) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

434th out of 1,125 stocks

Surgical Appliances & Supplies Industry

9th out of 23 stocks

3.5

Analyst's Opinion

Consensus Rating
Conformis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.50, Conformis has a forecasted upside of 313.7% from its current price of $0.36.
Amount of Analyst Coverage
Conformis has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.96% of the float of Conformis has been sold short.
Short Interest Ratio / Days to Cover
Conformis has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Conformis has recently decreased by 30.33%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Conformis does not currently pay a dividend.
Dividend Growth
Conformis does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CFMS.

1.7

News and Social Media Coverage

News Sentiment
Conformis has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 17 news articles for Conformis this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for CFMS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Conformis to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Conformis insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.40% of the stock of Conformis is held by insiders.
Percentage Held by Institutions
51.01% of the stock of Conformis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Conformis are expected to grow in the coming year, from ($0.32) to ($0.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Conformis is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Conformis is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Conformis has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Conformis (NASDAQ:CFMS) Stock

Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.

Wall Street Analyst Weigh In

CFMS has been the subject of a number of analyst reports. Canaccord Genuity Group cut their price objective on Conformis from $2.00 to $1.00 and set a "buy" rating for the company in a report on Thursday. StockNews.com initiated coverage on Conformis in a report on Tuesday, August 9th. They set a "hold" rating for the company.

Conformis Price Performance

Shares of NASDAQ:CFMS traded down $0.01 during midday trading on Monday, reaching $0.36. The company's stock had a trading volume of 7,549 shares, compared to its average volume of 761,257. Conformis has a fifty-two week low of $0.25 and a fifty-two week high of $1.96. The company has a market capitalization of $67.02 million, a P/E ratio of -1.09 and a beta of 1.25. The company has a debt-to-equity ratio of 0.28, a current ratio of 5.71 and a quick ratio of 4.77. The business's fifty day simple moving average is $0.32 and its 200-day simple moving average is $0.48.

Conformis (NASDAQ:CFMS - Get Rating) last announced its earnings results on Monday, August 8th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). Conformis had a negative net margin of 99.97% and a negative return on equity of 64.59%. During the same period last year, the business earned $0.21 earnings per share. As a group, equities research analysts expect that Conformis will post -0.32 EPS for the current fiscal year.

Receive CFMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conformis and its competitors with MarketBeat's FREE daily newsletter.

CFMS Stock News Headlines

August 14, 2022 | americanbankingnews.com

FY2022 EPS Estimates for Conformis, Inc. Decreased by Oppenheimer (NASDAQ:CFMS)

August 13, 2022 | finance.yahoo.com

Investors in Conformis (NASDAQ:CFMS) from five years ago are still down 89%, even after 32% gain this past week

August 13, 2022 | americanbankingnews.com

Canaccord Genuity Group Lowers Conformis (NASDAQ:CFMS) Price Target to $1.00

August 10, 2022 | americanbankingnews.com

Conformis (NASDAQ:CFMS) Receives New Coverage from Analysts at StockNews.com

August 9, 2022 | benzinga.com

Recap: Conformis Q2 Earnings - Benzinga

August 9, 2022 | in.investing.com

ConforMIS Inc Misses Q2 EPS by 1c By Investing.com - Investing.com India

August 9, 2022 | streetinsider.com

ConforMIS Inc (CFMS) Misses Q2 EPS by 1c - StreetInsider.com

August 9, 2022 | seekingalpha.com

ConforMIS GAAP EPS of -$0.09 misses by $0.01, revenue of $15.3M beats by $0.15M - Seeking Alpha

August 8, 2022 | globenewswire.com

Conformis Reports Second Quarter 2022 Financial Results - GlobeNewswire

August 8, 2022 | finance.yahoo.com

Conformis Reports Second Quarter 2022 Financial Results

August 7, 2022 | seekingalpha.com

ConforMIS Q2 2022 Earnings Preview

August 6, 2022 | americanbankingnews.com

Conformis (CFMS) to Release Earnings on Monday

August 4, 2022 | americanbankingnews.com

Short Interest in Conformis, Inc. (NASDAQ:CFMS) Decreases By 17.0%

August 2, 2022 | finance.yahoo.com

Conformis Shares Jump On Personalized Orthopedic Implants Contract

August 2, 2022 | finance.yahoo.com

Conformis Announces New Agreement with Vizient for Personalized Orthopedic Implants - Yahoo Finance

August 1, 2022 | globenewswire.com

Conformis Announces New Agreement with Vizient for Personalized Orthopedic Implants - GlobeNewswire

August 1, 2022 | finance.yahoo.com

Conformis Announces New Agreement with Vizient for Personalized Orthopedic Implants

August 1, 2022 | benzinga.com

Conformis Granted FDA 510(k) Premarket Notification For 'Identity Imprint Knee Replacement System' - Benzinga

July 28, 2022 | benzinga.com

Conformis, Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference - Benzinga

July 28, 2022 | finance.yahoo.com

Conformis, Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference

July 26, 2022 | americanbankingnews.com

StockNews.com Initiates Coverage on Conformis (NASDAQ:CFMS)

July 5, 2022 | globenewswire.com

Conformis, Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022 - GlobeNewswire

July 5, 2022 | finance.yahoo.com

Conformis, Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022

June 16, 2022 | globenewswire.com

The US has the Highest Number of Knee Reconstruction Pipeline Products | GlobalData Plc - GlobeNewswire

June 8, 2022 | uk.finance.yahoo.com

Worldwide Trauma Implants Industry to 2031 - Featuring Conformis, Orthofix Medical and Acumed Among Others - Yahoo Finance UK

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CFMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conformis and its competitors with MarketBeat's FREE daily newsletter.

CFMS Company Calendar

Last Earnings: 8/08/2022
Today: 8/16/2022
Next Earnings (Estimated): 11/02/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical appliances & supplies
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CFMS
CUSIP: N/A
CIK: 1305773
Web: www.conformis.com
Phone: (781) 345-9001
Fax: 781-345-0147
Employees: 310
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $1.50
High Stock Price Forecast: $2.00
Low Stock Price Forecast: $1.00
Forecasted Upside/Downside: +313.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-2,410,000.00
Net Margins: -99.97%
Pretax Margin: -99.95%
Return on Equity: -64.59%
Return on Assets: -44.09%

Debt

Debt-to-Equity Ratio: 0.28
Current Ratio: 5.71
Quick Ratio: 4.77

Sales & Book Value

Annual Sales: $99.86 million
Price / Sales: 0.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.54 per share
Price / Book: 0.67

Miscellaneous

Outstanding Shares: 188,000,000
Free Float: 181,604,000
Market Cap: $68.17 million
Optionable: Not Optionable
Beta: 1.25

Key Executives

Mr. Mark A. Augusti (Age 56)
CEO, Pres & Director
Comp: $1.22M
Mr. Robert S Howe (Age 52)
CFO & Treasurer
Comp: $524.91k
Mr. Michael Fillion
Chief Operating Officer
Ms. Denise E. Pedulla J.D. (Age 62)
M.P.H., Chief Legal Officer & Corp. Sec.
Mr. Farzin Khaghani
VP of U.S. Marketing
Ms. Allison Baker
Sr. Director of HR
Eric Rickenbach
Sr. VP of US Sales
Mr. Terrance Wong
Sr. VP of Engineering & Regulatory
Ms. Erin Henry (Age 37)
Corp. Controller
Ms. Christine Desrochers
Corp. Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CFMS Stock - Frequently Asked Questions

Should I buy or sell Conformis stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Conformis in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CFMS shares.
View CFMS analyst ratings or view top-rated stocks.
What is Conformis' stock price forecast for 2022?: 2 brokerages have issued 1-year target prices for Conformis' stock. Their CFMS share price forecasts range from $1.00 to $2.00. On average, they anticipate the company's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 313.7% from the stock's current price.
View analysts price targets for CFMS or view top-rated stocks among Wall Street analysts.
How have CFMS shares performed in 2022?: Conformis' stock was trading at $0.7610 at the start of the year. Since then, CFMS shares have decreased by 52.4% and is now trading at $0.3626.
View the best growth stocks for 2022 here.
When is Conformis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our CFMS earnings forecast.
How were Conformis' earnings last quarter?: Conformis, Inc. (NASDAQ:CFMS) posted its earnings results on Monday, August, 8th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.01. Conformis had a negative net margin of 99.97% and a negative trailing twelve-month return on equity of 64.59%. During the same period in the previous year, the firm posted $0.21 EPS.
What is Mark Augusti's approval rating as Conformis' CEO?: 15 employees have rated Conformis Chief Executive Officer Mark Augusti on Glassdoor.com. Mark Augusti has an approval rating of 55% among the company's employees. This puts Mark Augusti in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Conformis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Conformis investors own include Advanced Micro Devices (AMD), Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Trevena (TRVN), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and AT&T (T).
When did Conformis IPO?: (CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.
What is Conformis' stock symbol?: Conformis trades on the NASDAQ under the ticker symbol "CFMS."
Who are Conformis' major shareholders?: Conformis' stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (7.00%), Renaissance Technologies LLC (2.43%), Granite Point Capital Management L.P. (0.92%), Avidian Wealth Solutions LLC (0.47%), Connor Clark & Lunn Investment Management Ltd. (0.31%) and Millennium Management LLC (0.24%). Insiders that own company stock include Erin Henry, J Brent Alldredge, Kenneth P Fallon III, Mark A Augusti, Mark A Augusti, Paul S Weiner and Robert S Howe.
View institutional ownership trends.
How do I buy shares of Conformis?: Shares of CFMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Conformis' stock price today?: One share of CFMS stock can currently be purchased for approximately $0.36.
How much money does Conformis make?: Conformis (NASDAQ:CFMS) has a market capitalization of $68.17 million and generates $99.86 million in revenue each year. The medical instruments supplier earns $-2,410,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.
How many employees does Conformis have?: The company employs 310 workers across the globe.
How can I contact Conformis?: Conformis' mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The official website for the company is www.conformis.com. The medical instruments supplier can be reached via phone at (781) 345-9001, via email at ir@conformis.com, or via fax at 781-345-0147.

This page (NASDAQ:CFMS) was last updated on 8/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Conformis - CFMS Stock Forecast, Price & News

Conformis MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month